Meningitis Simultaneously Due to Cryptococcus neoformans and Mycobacterium tuberculosis in an Immunosuppressed Patient

Sergio Castaño*, Noemi Legaristi, Alejandro Martín and Ana Tejero Mogena

Intensive Care Department, Araba University Hospital, C/ Olaguibel, 29 01004 Vitoria, Spain

Abstract

A 51-year-old white female patient was admitted to our Intensive Care Unit, who was originally referred from Nephrology department due to neurological impairment. She had chronic renal failure and was being treated with immunosuppressants (tacrolium and prednisone) because she had undergone a cadaveric kidney transplantation in the past. The previous week she had been discharged after being treated for tuberculosis but she developed new symptoms including nausea, vomiting and hepatotoxicity due to the antituberculous treatment, which had to be finally stopped. Her abdominal symptomatology improved, however, she developed neurological impairment, refractory headache and tremors. On admission her temperature was 37.5°C and Glasgow coma score 13.

Table 1: Blood and CSF tests analysis.

| Blood tests | 1st CSF tests | 2nd CSF tests |
|-------------|---------------|---------------|
| Creatinine 4 mg/dL | Glucose 44 mg/dL | Glucose 60 mg/dL |
| Urea 73 mg/dL | Total protein 167.1 mg/dL | Total protein 152 mg/dL |
| AST 89 U/L | ADA 5 U/L | ADA 15 U/L |
| ALT 396 U/L | Red cell count 12/cumm | Red cell count 7/cumm |
| White blood cell count 14900/cumm | White cell count 126/ cumm (18% lymphocytes, 62% neutrophils) | White cell count 100/ cumm (65% lymphocytes, 35% neutrophils) |

Discussion

The incidence of infections Caused by Cryptococcus neoformans has increased over the past 20 years as a result of Human Immunodeficiency Virus epidemic and the raise of immunosuppressive therapies. It predominates in male patients, and is uncommon in immunocompetent patients [1,2].

The upper respiratory tract is the gateway for these infections in most cases; in the socket, the fungus can cause an inflammatory process that can be completely asymptomatic or can produce mild respiratory symptoms. A weak cellular immune response allows the fungus to spread through the systemic circulation and disseminates to the brain [3].

The insidious clinical signs are difficult to diagnose. It should be suspected in any immunocompromised patient who presents fever and signs/symptoms related to central nervous system. The symptomatology is variable, some patients have symptoms several months before the diagnosis, while others have an acute illness for only a few days. The subacute or chronic onset is more frequent and it includes headache, fever, chills, personality changes and memory leak. It usually occurs in patients that have risk factors for acquiring the infection [4]. Clinically, according to some published series, headache occurs in 100% of patients, and neurological impairment, meningeal signs, and involvement of cranial nerves in 22%, being 27% of mortality rate. Lumbar puncture is required for diagnosis, with CSF usually

Keywords: Tuberculosis meningitis; Cryptococcal meningitis
showing a moderate increase of the opening pressure; most patients have CSF lymphocytic pleocytosis (>100 cells/mL), moderate increase of CSF protein levels, and glucose consumption [5]. CSF analysis with India ink staining allows diagnosis of 50% of patients (HIV sensitivity is 73%) [5] and cryptococcal antigen test on CSF suggests the presence of cryptococcal infection before the culture tests are completed. The diagnosis is definitively established by culturing the microorganism in the cerebrospinal fluid [5]; it is also the most sensitive tool to assess treatment response with an average growing time of 3–4 days for yeasts.

Intracranial hypertension with or without multifactorial hydrocephalus is one of the complications that can occur, and it sometimes requires external ventricular drainage [6]. It is important to consider that after treatment, the India ink staining test can persist positive for up to two years, in spite of CSF cultures being negative [7].

Mycobacterial cultures can result in delay of the diagnostic and, considering the seriousness of subacute/chronic meningitis, the empirical treatment should focus on those microorganisms that are more frequently related to these kinds of infections. Rapid diagnostic tests can aid the choice of the right treatment for the condition. Tuberculous meningitis and fungal infections of central nervous system are difficult to differentiate because of the cytochemical CSF tests and clinical signs being very similar. For the differential diagnosis, latex tests for identifying antigens discussed above are very helpful. In patients with tuberculous meningitis the polymerase chain reaction test is more sensitive than the microscopic test and the culture. We must not forget the adenosine deaminase (ADA) enzyme which is associated with diseases that produce a cellular immune response; its determination may be helpful for the diagnosis of TB meningitis. The sensitivity and specificity of CSF culture in tuberculous meningitis and cryptococcal meningitis increase by repeating cultures of large volumes (up to 25 ml) of CSF [8].

Treatment should include antifungal therapy, measures for the management of ICP and reduction of immunosuppressive therapy. In contrast to the antifungal treatment, the induction therapy differs: liposomal amphotericin B + flucytosine (2 weeks), consolidation therapy: fluconazole (8 weeks) and maintenance therapy: fluconazole + liposomal amphotericin B + flucytosine (2 weeks), consolidation therapy: fluconazole (up to 25 ml) of CSF [8].

There are few publications that address co-infection cases of cryptococcal and tuberculosis in the central nervous system. The possibility of co-infection of the central nervous system must be considered if the evolution is unfavorable [11].

**Conclusion**

Considering the facts presented in our case report, our recommendation is to consider empirical cryptococcal meningoencephalitis treatment until the microbiological findings for immunocompromised patients that develop subacute meningitis with mononuclear pleocytosis, raised protein levels and glucose consumption in CSF analysis are available. The serological CSF latex test is very sensitive for the diagnosis, it is quick and easy to interpret and could be very useful when choosing the most appropriate empirical treatment.

**References**

1. Gaona-Flores VA (2013) Central nervous system and Cryptococcus neoformans. N Am J Med Sci 5: 492-493.
2. Shinjoh M, Miyairi I, Sakurai M, Takahashi M, Araya-su D, et al. (2005) Cryptococcal meningitis in an immunocompetent child. Eur J Pediatr 164: 596-597.
3. Vázquez TO, Martínez BI, Campos RT (2005) Cryptococosis. Historia natural y estado actual del tratamiento. Acta Pediatr Mex 26: 18-28.
4. Cox GM, Perfect JR, Kauffman CA, Thomer AR (2013) Clinical manifestations and diagnosis of Cryptococcus neoformans meningoencephalitis in HIV seronegative patients. UpToDate.
5. Arias BG, Montero LAZ (2011) Meningeal cryptococcosis: clinical and laboratory Characteristics. Acta Neurol Colomb 27: 9-27.
6. Guevara-Campos J, González-Guevara L, Urbéz-Cano J, Fenin S (2009) Cryptococcus neoformans meningoencephalitis in immunocompetent schoolchildren. Invest Clin 50: 231-239.
7. Tija TL, Yewo YK, Tan CB (1985) Cryptococcal meningitis. J Neurol Neurosurg Psychiatry 48: 853-858.
8. Codina MG, De Cueto M, Echevarría JE, Vicente D, Prats G (2010) Microbiological diagnosis of central nervous system infections. Enfermedades infecciosas y microbiología clínicas 29: 20-400.
9. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, et al. (2010) Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis 50: 291-322.
10. Cox GM, Perfect JR, Kauffman CA, Thomer AR, Kaplan SL (2013) Treatment of Cryptococcus neoformans meningoencephalitis and disseminated infection in HIV seronegative patients. UpToDate.
11. Cánovas DG, Araújo SB, Díaz RB, Fontanillas JR (2009) Association of tuberculous meningitis and cryptococcal meningitis in HIV-infected patient. Med Clin (Barc) 133: 360-362.